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Abstract 
The pathogenesis of MS involves alterations to multiple pathways and processes, which represent a 
significant challenge for developing more effective therapies. Systems biology approaches that 
study pathway dysregulation will offer benefits by integrating in molecular networks and dynamic 
models with current biological knowledge for understanding disease heterogeneity and response to 
therapy. In MS, abnormalities have been identified in several cytokine signaling pathways, as well 
as those of other immune receptors. Among the downstream molecules implicated are Jak/Stat, NF-
Kb, ERK1/3, p38 or Jun/Fos. Together, these data suggest that MS is likely to be associated with 
abnormalities in apoptosis / cell death, microglia activation, blood-brain barrier functioning, 
immune responses, cytokine production, and/or oxidative stress. While current MS drugs target 
some of these pathways, others remain untouched. Here, we propose a pragmatic systems analysis 
approach that involves the large-scale extraction of processes and pathways relevant to MS. This 
data serves as a scaffold upon which computational modeling can be performed to identify disease 
subgroups based in the contribution of different processes. Such an analysis, targeting these relevant 
MS signaling pathways, offers the opportunity to accelerate the development of novel individual or 
combination therapies. 
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Introduction 
Multiple Sclerosis (MS) is a chronic disease that is known to involve both inflammatory and 
neurodegenerative responses. Despite the significant progress made in recent decades, we are still 
relatively far from achieving a comprehensive understanding of the pathogenesis of this disease. 
The revolution in molecular biology, immunology and genetics, along with the development of new 
high-throughput technologies has driven the production of large amounts of data in recent years. 
However, while numerous genes and proteins have been associated with the disease, significant 
gaps remain in the quest to understand the pathological mechanisms responsible for MS. Although 
there is still hope that new studies will reveal specific genes, proteins or cells that will explain an 
important proportion of the causes of the disease, current perspectives suggest that we already have 
identified the majority of cells and molecules involved, and that what is urgently needed is to 
integrate the available and any future data into a comprehensive dynamic picture of MS1.  
 
Unfortunately, knowing that a gene or cell type is associated with MS is far from providing an 
explanation about the disease. This is related to the fact that genes or proteins associated with MS to 
date are not mutated and therefore they do play the physiological role expected for them, 
complicating the analysis2. Moreover, in a complex disease such as MS, genes, proteins and cells 
dynamically interact with each other in response to the stimuli and challenges the immune and 
nervous system face3. This quantitative and dynamic information is extremely difficult to capture 
from patients and even from animal models. Second, each individual harbors a different genetic 
background and also the development of the immune and nervous system is customized for their 
environment during development, being one of the basis of disease heterogeneity. Therefore, 
without the integration of molecular information in pathways and considering molecular and 
cellular heterogeneity, it will be difficult to achieve a good understanding of the pathogenesis of 
MS. At the individual patient level, it will be critical to collect personalized data to customize the 
analysis to pave the way towards stratified medicine. 
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Systems biology approaches may offer important benefits integrating current biological knowledge 
with clinical information and data on therapeutic responses, thereby allowing models to be 
generated that might help explain the pathogenesis of the disease3, 4. Therefore, in this review we 
will focus on how a systems biology approach applied to medicine (systems medicine) from the 
pathway perspective, incorporating molecular information about MS pathogenesis and drug targets, 
could improve our understanding of the disease and help in the development or identification of 
new improved therapies.  
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Pathways regulating MS pathogenesis: a puzzle of the immune system, the CNS and missing 
pieces  
Decades of cellular and molecular research in the field of MS have revealed many genes, proteins 
and cell subpopulations of the immune system associated with the disease, and such information has 
expanded massively with the new omics technologies. In order to identify the pathways involved in 
a given disease, abundant information is available in databases such as Gene-Disease Association 
Database, the Protein Sequence Database, the Comparative Toxicogenomics Database, the Online 
Mendelian Inheritance in Man, the Genetic Association Database, or the Literature-derived Human 
Gene-Disease Network. Moreover, genetic susceptibility for MS has been revealed by genome 
association studies (GWAS) and the ImmunoChip study in MS, which have identified more than 
100 SNPs associated with the disease5, 6, which have been implicated mainly in immune system 
pathways (leukocyte activation, apoptosis, and positive regulation of macro-molecule metabolism, 
JAK-STAT signaling pathway, acute myeloid leukemia, and T cell receptor signaling)7. Moreover, 
several databases containing information about pathways are available such as the Kyoto 
Encyclopedia of Genes and Genomes (KEGG), Reactome, PathwayCommons or the 
ConsensusPathDB. Finally, chemoinformatic resources such as DrugBank, ChEMBL and Drug 
Information Online contain information about drugs, including their targets within human 
pathways. By combining the information available in these databases, more than 40 pathways 
associated with MS can be found (Fig. 1A). The overall picture obtained reveals the involvement of 
a wide range of cellular processes and pathways implicated: apoptosis / cell death, microglia 
activation, blood-brain barrier functioning, immune response, cytokine production, or oxidative 
stress. In addition, the search of these cellular processes can be combined with the targets of MS 
treatments, such as fingolimod, dimethyl-fumarate or interferon-beta. The targets of these therapies 
can be included by identifying the pathways that link them to the processes above, namely lipid-
mediated signaling and its crosstalk with survival and NF-Kb pathways, antioxidant pathways and 
the Stat-mediated IFNb response, respectively. Interestingly, pathway analysis revealed certain 
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processes that are not yet targeted by current therapies, e.g. the Notch pathway 8-10. Another 
pathway related with MS is vitamin D metabolism, and at present there are several trials testing the 
efficacy of vitamin D supplementation	  11.  
 
New roles in MS of components in known pathways 
Once data is retrieved from databases, bioinformatic tools allow identification of interactions 
between genes, proteins and cells that can be used as hypotheses (Fig1B). For instance, and of 
pivotal clinical importance, these tools help to study the involvement of CNS pathways in MS 
pathogenesis. MS is a condition associated with substantial neuronal and axonal damage, and this 
neurodegeneration probably drives long-term neurological disability12. Hence, pathways that are 
related to neuronal death and axonal damage may be of particular interest for the development of 
neuroprotective therapies, an approach pursued for decades without success to date. Because our 
current understanding of the immune system is significantly more advanced than that of the CNS, 
automatic searches of databases have been likely to reveal significantly more pathways associated 
with the immune system than the nervous system. Moreover, the study of MS has been focused 
strongly on its immune aspects, as well as on the development of immunomodulatory medicines 
that target the inflammatory process and prevent relapses. Fortunately, the picture is now changing, 
and some of the pathways associated with MS relate to CNS damage, including apoptosis, oxidative 
stress, or microglia activation. Potential neuroprotective therapies under development are aimed to 
target such pathways such as green tea catechin epigallocatechin-gallate, trophic factors, 
Methylthioadenosine or drugs enhancing remyelination 13-16. 
 
Patient-to-patient genetic variability hinders understanding of signalling pathways involved in 
MS. 
It is striking that the recent massive genetic studies (e.g. GWAS, Immunochip) explain so little of 
individual disease risk5, 6.  It is also surprising that no single MS therapeutic yet has had well 
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validated genetic stratification. We believe that this fact, common to many complex diseases, is at 
least in part due to the lack of a functional, network-based perspective to the pathogenesis of the 
disease. Signaling networks are very robust to variation in cells and their environment to enable 
cellular functioning. For instance, it has been shown that even clonal populations strongly vary in 
the concentration of the same protein 17. The cellular function regulated by that protein needs to 
remain unaltered for healthy cellular behavior, therefore a number of network motifs grant 
robustness to signaling networks such as negative feedback loops 18.  Other variations to which 
signaling pathways can be robust are genetic polymorphisms. Therefore, including genotyping 
data when modeling signaling pathways of MS patients is key to understanding MS pathogenesis.  
 
Furthermore, some pathways may not be etiologically relevant because they are associated due to 
co-segregation of alleles with diseases. One approach for integrating the role of genetic 
susceptibility in systems biology methods is by considering that risk alleles mildly modify the 
parameters governing the functioning of the pathways. Therefore, one single allele may not have a 
significant effect in a given pathway, but the collection of all the risk alleles in a given individual 
may influence the function of immune pathways to the level of producing autoimmune activation. 
These considerations may help to improve the prediction of autoimmune response at the individual 
level. The same reasoning may apply to the fact that no drug stratifies by any single risk allele, 
although this may change if new therapies target MS associated genes and one of the alleles 
modulate the biological effects of the drug. 
 
In summary, understanding how each individuals’ genetic polymorphisms lead to their specific 
signaling network activity would enable characterization of the different MS phenotypes. This 
would, however, suggest a further question: how does patient-to-patient variability in signaling 
activity affect drug efficacy? To answer this question, signaling networks need to be elucidated 
not only depending on donor genetic variability, but also in a cell-specific manner, thereby 
	   8	  
determining how each pathway contributes to the cell phenotype (pro-inflammatory, 
degeneration, repair), and to identify the missing steps (molecules and interactions) that 
participate in such MS pathways. For example, IL-10 is one of the main immunosuppressor 
cytokines but clinical trials with IL-10 failed to show benefits in MS, probably because IL-10 
receptor signaling is at least partially deregulated in immune cells19, and this can influence the 
individual response. We envision that a fine mapping of specific pathways such as cytokines 
pathways in specific cell types (e.g. CD4, CD8, B cells) in parallel with large high throughput 
studies will allow us to improve pathway annotation. Coupled computational modeling and 
experimental validation will enable characterization of signaling networks in a cell-type, donor 
and genetic variant specific manner, as reviewed in detail below. 
 
Other challenges in pathway analysis 
The fact that database searches identify many pathways associated with MS in immune cells 
might suggest that there is significant cross-talk between the major pathways within the same 
cell, with important proteins participating in several signaling cascades (Jak/Stat, NF-Kb, 
ERK1/2, p38, Jun/Fos). Crosstalk within pathways in the same cell is complex and thus difficult 
to study only based on existing experiments. Second, there is a substantial gap in our 
understanding of how such crosstalk interactions are translated into a cell-type specific response 
at the system level (e.g., interferon-beta produces different effects on macrophages and T cells, 
which are related with different clinical effects). Third, it is particularly difficult to make sense 
out of the existing MS data, since it is a disease that affects the arguably two most complex 
tissues/organ systems in our body, i.e. the immune system and the CNS, as described above. 
Fourth, annotation of gene function is still incomplete, and the role of the same genes in the CNS 
is often even less well understood or as yet unknown. For example, TNFα may have detrimental 
effects in the immune system in MS but they might also be beneficial in the CNS during 
remyelination 20. Indeed, TNFα promotes oligodendrocyte progenitor proliferation, as well as 
	   9	  
remyelination, which probably explain why the application of the TNF-antagonist lenercept 
produced an unexpected deterioration of MS 21. Finally, a principal limitation in pathway analysis 
using existing data for functional annotation is that these approaches do not provide a 
mechanistic model that can be simulated, hence hindering the prediction of novel signaling 
mechanisms. To solve the challenges described here, combined analysis of newly acquired 
experimental data and mathematical models can be used22.	  Next,	  we	  review	  in	  detail	  such	  predictive	  models. 
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Predictive and mechanistic models to understand MS pathogenesis and therapies 
The past decade has seen an explosion in the information regarding the cellular networks that 
transmit and process signals from the cell’s environment. To gain novel understanding of the basic 
mechanisms that the cell uses to integrate these signals, as well as how such mechanisms are 
impaired by disease, mechanistic –mathematical- models are a powerful tool	  23. The first step to 
mathematical modeling is a literature search to gather the current understanding regarding the 
molecular process of interest, in this case MS. To that end, we can query public resources, a process 
that yields the pathways known to be involved in MS, which in turn are combined to form a 
signaling network. Signaling networks can be used as initial scaffolds upon which we can formulate 
mechanistic hypothesis and evaluate similarity with experimental data and disease-driven changes 
(Fig. 2, upper row). Therefore, experimental data needs to be acquired that measures as many 
readouts as possible relevant to the disease of study, i.e. present in the signaling network. To that 
end, phosphoproteomic measurements are key in the analysis of signaling pathways because 
measuring abundance of phosphorylated proteins closely indicates propagation of a signal through a 
pathway and can be used in functional models24. Previous work in the field has provided clear 
examples that phosphoproteomic analysis is able to provide accurate models of some pathways in 
cells such as hepatocytes 25.  Bead-­‐based	  ELISA	  assays	  of	  xMAP	  technology	  (Luminex,	  Austin,	  TX)	  are	  well	  suited	  for	  this	  task	  24,	  enabling	  measurement	  of	  the	  abundance	  of	  a	  large	  number	  of	  phosphorylated	  proteins	  in	  the	  MS	  pathways	  above-­‐mentioned,	  in	  immune	  cells	  of	  individual	  patients	  of	  differents	  cohorts.	  Combining	  phosphoproteomics	  with	  genotyping	  in	  mathematical	  models,	  both	  the	  activity	  of	  MS	  pathways	  and	  the	  genetic	  variability	  that	  may	  explain	  the	  patient-to-patient difference in terms of response to treatment	  can	  be	  studied	  (Fig.	  2,	  upper	  row).	  Once a signaling network has been assembled via literature search, and the data to 
compare it has to been measured, mathematical approaches enable formalization of the network as a 
mechanistic model. Intuitively, the formulation as mathematical model of such a signaling network 
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addresses two limitations: they are neither specific to individual patients (or even often to specific 
cell types), nor are they computable, i.e., can be used to predict the outcome of perturbations with 
drugs and ligands.  
 
Several mathematical modeling approaches have become well established in the field of systems 
biology and can be applied to signaling pathways, ranging from logic to physicochemical models 	  
26. The lack of quantitative information for building the models can be bridged by using logic 
(Boolean) modeling, which includes only causal information and that due to this simplicity, has 
many fewer parameters (quantitative properties) to evaluate. This advantage can be used to 
represent large signaling networks that can be generated with limited data 27. To implement logic 
models, tools such as CellNOpt	  28 enable formalization of the signaling network as logic model and 
subsequent simulation. Next, these tools enable calibration of the model, which is performed by 
changing the network topology, i.e. the shape of the network in terms of the interactions between 
the present signaling intermediates. These changes consist in introducing or removing interactions, 
and systematic comparison of the simulations upon different topologies against the experimental 
data predicts the topology that best fits the data. The simplicity in logic modeling that enables 
simulation of large networks at the same time hinders highly detailed modeling of small networks. 
In more detailed analyses, appropriate tools are physicochemical models that describe the 
underlying biochemical reactions explicitly 23, 29, 30. Here the model parameters are quantitative 
characteristics such as kinetic rates of the reactions that they represent, which are revealed by model 
calibration against the experimental data. In both modeling approaches, the main challenge lies in 
calibrating the model in order to make the model specific for MS, while at the same time 
determining the factors contributing to patient-to-patient variability. To address patient-to-patient 
variability, instead of starting from a single signaling network one solution is to calibrate an 
ensemble of networks featuring a high number of different starting topologies in order to test many 
different hypotheses that are compared separately to the xMAP and genotype of single patients31	  ,	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  including	  in	  these	  signaling	  topologies	  the	  mechanisms	  that	  grant	  robustness	  to	  signaling	  pathways,	  such	  as	  negative	  feedback	  loops.	  Thereby,	  we	  could	  determine	  which	  of	  the	  ensemble	  of	  topologies	  best	  fits	  each	  individual	  patient	  (Fig	  2,	  middle	  row). Overall, the 
modeling of signaling pathways in MS, using either logic networks or mathematical models, offers 
the opportunity to predict new signaling mechanisms that help better understand disease 
pathogenesis. For example, a recent mathematical model of the type 1 interferon pathway revealed 
the translocation of Stat-1 to the nucleus as the most critical step in the signaling of IFN-b, a finding 
that could not be predicted solely based in molecular analysis but required dynamic simulations32. 
 
Drug development and combination therapy in predictive models of MS  
One obvious question is if recent technological developments have provided a large amount of data 
about MS, why is drug discovery still so complex and provides so limited results? Although the 
limitations of the drug discovery process have been reviewed in detail33, several specific issues 
regarding how biological information is translated into models of the disease and pathways are of 
importance. In the process of developing useful pathway models for drug development it is critical 
to take in consideration many aspects that at present are not well covered, such as (i) the availability 
of quantitative and kinetic data from human/patients; (ii) integration of individual heterogeneity and 
genetic background for defining the response to therapy, or (iii) the need to develop approaches for 
integrating and simulating complex networks of not just cells but also tissues. As described in Fig. 
2, here we propose that coupling several omics and genotyping to mathematical models of signaling 
networks can address these issues. Further, existent drugs can be repurposed to target MS-related 
components by including their targets in a signaling network that can then be formalized as a 
mathematical model and simulated. This would enable to test millions of different options in terms 
of topology of signaling networks, therapeutic regimens, and drug/target combinations. This should 
allow prediction of the signaling mechanisms by which these existing drugs could be repurposed to 
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MS, discard therapeutic approaches that may not work and point at the ones that deserve careful 
experimental and clinical testing. 
 
Given the complexity and heterogeneity of MS, combination therapies that modulate various 
pathogenic pathways simultaneously are an attractive treatment strategy 34. A synergistic effect of 
two drugs with different mechanisms of action may potentially improve efficacy, safety and 
tolerability. By contrast, defining the optimal combination of drugs requires a more comprehensive 
understanding of the networks of pathways in different cells initiating and driving the progression 
of MS, an effort that can be addressed using systems biology techniques 35. The integration of 
clinical, biological and pharmaceutical data in computational models that reproduce the complexity 
of such diseases can be used to identify synergistic effects by evaluating the downstream effects of 
drugs 36. 
 
Finally, another significant challenge in improving drug development is predicting side-effects of 
therapies. Predictive toxicity was something highly theoretical until recently, but in the last years 
new significant insights have been provided by developing new algorithms combining drug 
databases and safety databases. Prior knowledge extracted from such databases can be introduced in 
mathematical models (Fig. 2) that are starting to provide useful predictions regarding potential side-
effects that can be tested in preclinical or early clinical phases of drug development 37, 38	  . However, 
this complex issue is still far from being solved. 
 
Conclusions 
The pathogenesis of MS is complex, involving hundreds of genes and proteins that act in numerous 
pathways and evolve along time and disease progression, each of which can contribute to the 
phenotype. These genes and proteins may respond distinctly to different therapies, and even behave 
differently in different patients. In order to integrate current knowledge and generate a 
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comprehensive model of MS pathogenesis, pathway analysis represents a promising strategy. 
Combining experimental and medical data with distinct systems biology approaches should provide 
new insights on disease pathogenesis, allow us to screen in silico new drugs for repurposing, as well 
as test combinations of drugs, before exposing patients to therapy. 
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Figure legends 
Figure 1. Signaling pathways associated with MS. A) An example of the pathways implicated in 
MS that can be indentified from databases. Right column shows the heatmap of the pathways 
associated with MS and the left columns the heatmap of the pathways associated with each of the 
drugs. On the right, each cluster is followed by the list of the pathways it includes (in bold the 
pathways specifically target by a drug). Blue squares: known mechanisms of action for a given 
drug. Green box: pathways associated with MS but not targeted by any drug. B) Integration of 
signaling pathways implicated in MS in network models: the genes/proteins associated with MS are 
displayed in orange, drugs in green; and the main MS pathways targeted by therapies in yellow. 
Figure 2. Pipeline for the identification of new therapies based on the modeling of signaling 
pathways associated with MS and MS drugs. Flow from first to second row panels: 
experimental set-ups, such as proteomics and genotyping, can be tailored to interrogate MS specific 
signatures in terms of phosphoproteomics (rows, phosphorylation profile of specific proteins e.g. 
xMAP assays; Columns, MS-related treatments) and the risk variants. A literature search enables 
MS- and immune-specific pathways to be compiled and drug-protein networks can be assembled 
(the hot scale shows the density of proteins in the signaling pathways, and the upper layer shows 
green and blue clusters of proteins targeted by MS-related drugs). Flow from second to third row 
panels: logic and dynamic models can be constructed based on MS- and immune-specific signaling 
pathways. In order to study how signaling is deregulated in MS, one model can be calibrated 
against a patient-specific dataset, thereby yielding an ensemble of patient-specific models that 
enables common signaling mechanisms and those that explain patient-to-patient variability to be 
discriminated. In parallel, the signaling pathways and drug-protein networks can be used as an input 
for machine learning approaches in order to reposition existing drugs that can be used to infer new 
drug indications or to predict toxicity. From new drug indication to model: literature search of 
existing drugs and their targets, combined with search of those targets in MS-specific networks 
yields MS-specific drug-protein networks, which suggests new drug indications by identifying the 
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interactions from drug targets to MS networks. These newly-indicated drugs can then be introduced 
in the predictive models to understand their mechanisms of action in order to select those drugs 
with the best potential efficacy. 
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